Back to News
Market Impact: 0.25
Regeneron's Ubamatamab, Trevogrumab Show Strong Results In Cancer And Obesity Studies
Source: Nasdaq
Healthcare & BiotechProduct Launches
Regeneron reported new clinical data for ubamatamab in advanced low-grade serous ovarian cancer and for trevogrumab in people with obesity receiving semaglutide. The article provides no efficacy, safety, or financial data, limiting immediate assessment of the programs' commercial significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
REGN0.45
More News
- Jefferies raises Regeneron stock price target to $930 on partnership
- Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
- Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
- Why the media’s whisper campaign about a Goldman Sachs change at the top is misleading gossip, at best
- One of our most recent defensive buys cleared a hurdle and its stock jumped